Literature DB >> 25708578

Radiotherapy for high-risk prostate cancer.

Jahan J Mohiuddin1, Brock R Baker1, Ronald C Chen1.   

Abstract

The combination of radiation treatment and long-term androgen deprivation therapy (ADT) has been shown in multiple clinical trials to prolong overall survival in men with high-risk prostate cancer compared with either treatment alone. New radiation technologies enable the safe delivery of high radiation doses that improve cancer control compared with lower radiation doses. Based on the results of multiple randomized trials, clinical practice guidelines for high-risk prostate cancer recommend total radiation doses of at least 75.6 Gy, with long-term (2-3 years) ADT. Ongoing research into hypofractionated radiation treatment, whole-pelvic radiation, and combinations of radiation with novel hormonal agents could further improve cancer control and survival outcomes for patients with high-risk prostate cancer.

Entities:  

Mesh：

Year:  2015        PMID： 25708578     DOI： 10.1038/nrurol.2015.25

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  87 in total

1.  Insulin sensitivity during combined androgen blockade for prostate cancer.

Authors:  Matthew R Smith; Hang Lee; David M Nathan
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

2.  Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Authors:  James W Denham; Allison Steigler; David S Lamb; David Joseph; Sandra Turner; John Matthews; Chris Atkinson; John North; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Catherine D'Este
Journal:  Lancet Oncol       Date:  2011-05       Impact factor: 41.316

3.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

4.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

5.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Authors:  Frances Dockery; Christopher J Bulpitt; Sanjiv Agarwal; Mandy Donaldson; Chakravarthi Rajkumar
Journal:  Clin Sci (Lond)       Date:  2003-02       Impact factor: 6.124

7.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

8.  Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.

Authors:  Mara Z Vitolins; Leah Griffin; W Vic Tomlinson; Jacqueline Vuky; Paul T Adams; Dawn Moose; Bart Frizzell; Glenn J Lesser; Michelle Naughton; James E Radford; Edward G Shaw
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

9.  Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.

Authors:  Patrick E Teloken; Michael Ohebshalom; Najeeb Mohideen; John P Mulhall
Journal:  J Urol       Date:  2007-10-15       Impact factor: 7.450

10.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321
View more
  11 in total

Review 1.  Pharmacological methods to transcriptionally modulate double-strand break DNA repair.

Authors:  Alanna R Kaplan; Peter M Glazer
Journal:  Int Rev Cell Mol Biol       Date:  2019-12-18       Impact factor: 6.813

Review 2.  The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer.

Authors:  Giorgio Gandaglia; Cesare Cozzarini; Alexandre Mottrie; Alberto Bossi; Nicola Fossati; Francesco Montorsi; Alberto Briganti
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

3.  Low-dose ionizing irradiation triggers apoptosis of undifferentiated spermatogonia in vivo and in vitro.

Authors:  Lixin Qi; Jiaxuan Li; Wei Le; Jinfu Zhang
Journal:  Transl Androl Urol       Date:  2019-12

4.  Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.

Authors:  Miguel Reis Ferreira; Atia Khan; Karen Thomas; Lesley Truelove; Helen McNair; Annie Gao; Chris C Parker; Robert Huddart; Margaret Bidmead; Ros Eeles; Vincent Khoo; Nicholas J van As; Vibeke N Hansen; David P Dearnaley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-08-02       Impact factor: 7.038

5.  Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment.

Authors:  Xia Li; Xiupeng Wang; Jun Zhang; Nobutaka Hanagata; Xuebin Wang; Qunhong Weng; Atsuo Ito; Yoshio Bando; Dmitri Golberg
Journal:  Nat Commun       Date:  2017-01-06       Impact factor: 14.919

6.  Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer.

Authors:  M R Ferreira; K Thomas; L Truelove; A Khan; C Parker; D P Dearnaley; S Gulliford
Journal:  Clin Oncol (R Coll Radiol)       Date:  2019-03-20       Impact factor: 4.126

7.  Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.

Authors:  Konjeti R Sekhar; Jian Wang; Michael L Freeman; Austin N Kirschner
Journal:  PLoS One       Date:  2019-04-01       Impact factor: 3.240

8.  Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.

Authors:  Yi Liu; Peipei Zhang; Yinghao Zhang; Lichuan Zheng; Wenbo Xu; Dongtao Hou; Zhengjun Kang
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

Review 9.  Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review.

Authors:  Stine Elleberg Petersen; Morten Høyer
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

Review 10.  Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.

Authors:  Thy Pham; Martin C Sadowski; Huika Li; Derek J Richard; Michael C d'Emden; Kerry Richard
Journal:  Exp Hematol Oncol       Date:  2016-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.